<DOC>
	<DOCNO>NCT02663089</DOCNO>
	<brief_summary>Batefenterol ( GSK961081 ) bifunctional bronchodilator develop treatment Chronic Obstructive Pulmonary Disease ( COPD ) . Absorption , metabolism excretion batefenterol study animal , vitro , previous clinical study ; however , elimination route metabolic pathway batefenterol fully elucidate human . This open-label , single centre , non-randomised , 2-period single-sequence crossover , mass balance study determine total radioactivity ( drug relate material ) plasma , rate extent excretion total radioactivity urine faeces total recovery radioactivity [ 14C ] GSK961081 administer single IV dose ( concomitant inhale non-radiolabelled dose ) single oral dose , healthy male subject . A total 6 healthy male subject enrol . The duration subject study 11 week , consist screen visit , 2 Treatment Periods , follow visit .</brief_summary>
	<brief_title>A Phase 1 ( Ph1 ) , Single Dose ( SD ) , GSK961081 Absorption , Distribution , Metabolism , Excretion ( ADME ) Study Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Between 30 55 year age inclusive , time signing informed consent . Healthy determine investigator medically qualify designee base medical evaluation include medical history , physical examination , vital sign , laboratory test , cardiac monitoring . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include investigator agree document find unlikely introduce additional risk factor interfere study procedure . A history regular bowel movement ( average one bowel movement per day ) . Body weight &gt; =50 kilogram ( kg ) body mass index ( BMI ) within range 19.031.0 kg/square metre ( m^2 ) ( inclusive ) Sex : Male Subjects female partner child bear potential must use condom time first dose study medication followup . Capable give sign informed consent describe protocol include compliance requirement restriction list consent form . Alanine aminotransferase ( ALT ) bilirubin &gt; 1.5xupper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Mean correct QT interval ( QTc ) &gt; 450 millisecond ( msec ) Any clinically relevant abnormality identify screen medical assessment ( physical examination/medical history ) , clinical laboratory test , 12lead ECG . A preexist condition ( ) interfere normal gastrointestinal ( GI ) anatomy motility , include constipation , malabsorption GI dysfunction may interfere absorption , distribution , metabolism elimination study drug . Subjects history cholecystectomy must exclude . At screening , supine blood pressure ( BP ) persistently high ( triplicate measurement least 2 min apart ) 140/90 millimetre mercury ( mmHg ) . At screening , supine mean HR outside range 4090 beat per minute ( BPM ) . Subject mentally legally incapacitate . A history respiratory disease ( e.g . history asthmatic symptom ) last 10 year . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) first dose study medication , unless opinion investigator GlaxoSmithKline ( GSK ) Medical Monitor medication interfere study procedure compromise subject safety . History regular alcohol consumption within 6 month study , define average weekly intake &gt; 21 unit . One unit equivalent 8 gram ( g ) alcohol : halfpint ( approximately 240 millilitre [ mL ] ) beer , 1 glass ( 125 mL ) wine 1 ( 25 mL ) measure spirit . Urinary cotinine level indicative smoking ; current smoker ; exsmokers give less 6 month ago history 10 packyears . Packyears = cigarette per day multiply number year smoke divide 20 . History sensitivity study medication component , history drug allergy , opinion investigator Medical Monitor , contraindicate subject 's participation . Presence hepatitis B surface antigen ( HBsAg ) , positive hepatitis C antibody test result screen within 3 month first dose study treatment . A positive test Human Immunodeficiency Virus ( HIV ) antibody A positive prestudy drug/alcohol screen . The subject participate clinical trial receive investigational product ( IP ) within 3 month first dose current study . Exposure four new chemical entity within 12 month subject 's first dose . Participation clinical trial involve administration 14Clabelled compound ( ) within last 12 month . A subject ' previous effective dose review medical investigator ensure risk contamination/carryover current study . Subjects received total body radiation dose great 5.0 millisievert ( mSv ) ( upper limit World Health Organization [ WHO ] category II ) exposure significant radiation ( e.g . serial x ray compute tomography [ CT ] scan , barium meal etc ) 12 month study . An occupation require monitor radiation exposure , nuclear medicine procedure excessive xrays within past 12 month . Unable refrain consumption red wine , Seville oranges , grapefruit grapefruit juice 7 day first dose study medication followup visit . Where participation study would result donation blood blood product excess 500 mL within 90 day period . Unwillingness inability follow procedure outline protocol , include use enterotest capsule .</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>total radioactivity</keyword>
	<keyword>[ 14C ] -GSK961081</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease ( COPD )</keyword>
	<keyword>Microtracer</keyword>
</DOC>